Innova Captab Limited (INNOVACAP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Innova Captab Limited (INNOVACAP) has a cash flow conversion efficiency ratio of 0.029x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs297.19 Million ≈ $3.21 Million USD) by net assets (Rs10.21 Billion ≈ $110.43 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Innova Captab Limited stock valuation for the company's overall valuation and market capitalisation.
Innova Captab Limited - Cash Flow Conversion Efficiency Trend (2018–2026)
This chart illustrates how Innova Captab Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Innova Captab Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Innova Captab Limited ranked by their cash flow conversion efficiency. Explore Innova Captab Limited (INNOVACAP) cash flow quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Center Laboratories
TWO:4123
|
0.002x |
|
Changzhou Galaxy Century Microelectronics Co Ltd
SHG:688689
|
0.006x |
|
China Hi-Tech Group Co Ltd
SHG:600730
|
-0.007x |
|
Propel Holdings Inc
TO:PRL
|
-0.053x |
|
Huachangda Intelligent Equipment Group Co Ltd
SHE:300278
|
0.035x |
|
Shenzhen Xinhao Photoelectricity Technology Co. Ltd
SHE:301051
|
N/A |
|
Vestis Corporation
NYSE:VSTS
|
0.036x |
|
SENORES PHARMACEUTICALS L
NSE:SENORES
|
0.025x |
Annual Cash Flow Conversion Efficiency for Innova Captab Limited (2018–2026)
The table below shows the annual cash flow conversion efficiency of Innova Captab Limited from 2018 to 2026. View today's stock price for Innova Captab Limited for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-03-31 | Rs10.91 Billion ≈ $117.97 Million |
Rs1.03 Billion ≈ $11.11 Million |
0.094x | +41.47% |
| 2025-03-31 | Rs9.59 Billion ≈ $103.76 Million |
Rs638.44 Million ≈ $6.90 Million |
0.067x | -62.22% |
| 2024-03-31 | Rs8.31 Billion ≈ $89.86 Million |
Rs1.46 Billion ≈ $15.83 Million |
0.176x | -14.57% |
| 2023-03-31 | Rs3.26 Billion ≈ $35.21 Million |
Rs671.24 Million ≈ $7.26 Million |
0.206x | -26.98% |
| 2022-03-31 | Rs2.09 Billion ≈ $22.56 Million |
Rs588.98 Million ≈ $6.37 Million |
0.282x | +7.15% |
| 2021-03-31 | Rs1.45 Billion ≈ $15.66 Million |
Rs381.60 Million ≈ $4.13 Million |
0.263x | +224.86% |
| 2020-03-31 | Rs3.80 Billion ≈ $41.06 Million |
Rs307.97 Million ≈ $3.33 Million |
0.081x | -86.89% |
| 2019-03-31 | Rs305.11 Million ≈ $3.30 Million |
Rs188.72 Million ≈ $2.04 Million |
0.619x | +138.16% |
| 2018-03-31 | Rs626.18 Million ≈ $6.77 Million |
Rs162.62 Million ≈ $1.76 Million |
0.260x | -- |
About Innova Captab Limited
Innova Captab Limited, an integrated pharmaceutical company, engages in the research and development, manufacture, distribution, and marketing of drugs in India and internationally. The company provides contract development and manufacturing organization services to Indian pharmaceutical companies. It is also offers various generic formulation products, including cephalosporins, proton pump inhib… Read more